Canaccord resumed coverage of Knight Therapeutics (KHTRF) with a Buy rating and C$9.50 price target after the company reported “a very strong set” of Q1 results. The company also took up its 2026 revenue guidance and maintained its outlook for a 15% adjusted EBITDA margin in 2026, the analyst noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KHTRF:
- Knight Therapeutics Doubles Down on Earnings Momentum
- Knight Therapeutics price target raised to C$8.50 from C$8 at RBC Capital
- Knight Therapeutics Posts Record 2025 Revenue, Sets Confident 2026 Outlook
- Knight Therapeutics sees FY26 revenue C$490M-C$510M
- Knight Therapeutics reports Q4 EPS C$0.09 vs. C$0.11 last year